Compound Danshen Dripping Pill for Treating Nonproliferative Diabetic Retinopathy: A Meta-Analysis of 13 Randomized Controlled Trials.

We located 13 RCTs and methodological quality was evaluated as high risk. Statistics indicated CDDP for treating DR was better than controls and DR risk was reduced 64% with CDDP (RR: 0.36, P = 0.68); retinal microaneurysms (MD = -4.32NO, P < 0.00001); retinal hemorrhages (MD = -0.70PD, P = 0.03); exudate improvements (MD = -0.09PD, P = 0.79); visual changes (MD = -0.12 letter, P = 0.006); FFA (RR: 0.40, P = 0.003). About GRADE, quality of evidence was "low." Conclusion. CDDP may be safe and efficacious for treating or delaying DR and may improve vision or delay vision loss.